Logo image of HURA

TUHURA BIOSCIENCES INC (HURA) Stock Fundamental Analysis

USA - NASDAQ:HURA - US8989201038 - Common Stock

2.47 USD
-0.09 (-3.52%)
Last: 10/16/2025, 1:44:39 PM
Fundamental Rating

1

Taking everything into account, HURA scores 1 out of 10 in our fundamental rating. HURA was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of HURA have multiple concerns. HURA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HURA has reported negative net income.
In the past year HURA has reported a negative cash flow from operations.
In the past 5 years HURA always reported negative net income.
HURA had a negative operating cash flow in each of the past 5 years.
HURA Yearly Net Income VS EBIT VS OCF VS FCFHURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -112.19%, HURA is not doing good in the industry: 78.17% of the companies in the same industry are doing better.
HURA has a worse Return On Equity (-199.71%) than 67.16% of its industry peers.
Industry RankSector Rank
ROA -112.19%
ROE -199.71%
ROIC N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
HURA Yearly ROA, ROE, ROICHURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HURA Yearly Profit, Operating, Gross MarginsHURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

HURA has less shares outstanding than it did 1 year ago.
HURA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for HURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HURA Yearly Shares OutstandingHURA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
HURA Yearly Total Debt VS Total AssetsHURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

HURA has an Altman-Z score of -3.36. This is a bad value and indicates that HURA is not financially healthy and even has some risk of bankruptcy.
HURA has a Altman-Z score of -3.36. This is comparable to the rest of the industry: HURA outperforms 44.22% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that HURA is not too dependend on debt financing.
The Debt to Equity ratio of HURA (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -3.36
ROIC/WACCN/A
WACCN/A
HURA Yearly LT Debt VS Equity VS FCFHURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.83 indicates that HURA may have some problems paying its short term obligations.
HURA's Current ratio of 0.83 is on the low side compared to the rest of the industry. HURA is outperformed by 89.18% of its industry peers.
A Quick Ratio of 0.83 indicates that HURA may have some problems paying its short term obligations.
HURA has a Quick ratio of 0.83. This is amonst the worse of the industry: HURA underperforms 88.99% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
HURA Yearly Current Assets VS Current LiabilitesHURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.66% over the past year.
EPS 1Y (TTM)44.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.99% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-42.39%
EPS Next 2Y-7.84%
EPS Next 3Y6.99%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HURA Yearly Revenue VS EstimatesHURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 20M 40M 60M
HURA Yearly EPS VS EstimatesHURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HURA Price Earnings VS Forward Price EarningsHURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HURA Per share dataHURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.84%
EPS Next 3Y6.99%

More info and screens

0

5. Dividend

5.1 Amount

HURA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TUHURA BIOSCIENCES INC

NASDAQ:HURA (10/16/2025, 1:44:39 PM)

2.47

-0.09 (-3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-06 2025-10-06/amc
Earnings (Next)11-12 2025-11-12
Inst Owners12.88%
Inst Owner Change0.32%
Ins Owners34.73%
Ins Owner ChangeN/A
Market Cap126.22M
Analysts82.22
Price Target11.54 (367.21%)
Short Float %7.21%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-52.55%
DP-0.01%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.8%
Min EPS beat(2)-62.53%
Max EPS beat(2)-47.06%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.75%
EPS NY rev (1m)-14.41%
EPS NY rev (3m)-19.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.49
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.84
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS0.38
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.19%
ROE -199.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z -3.36
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)139.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.53%
EPS Next Y-42.39%
EPS Next 2Y-7.84%
EPS Next 3Y6.99%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-308.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3862.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-185287%
OCF growth 3YN/A
OCF growth 5YN/A